1. Density, Risk Factors Predict Postmenopausal Breast Cancer
(Communities/Breast Mammary Gland)

... risk factors such as age, race, ethnicity, and family history appeared to be the best approach to estimating risk, the researchers said. Those found to be at high risk should start tamoxifen or raloxifene ...

2. New weapons in the war on osteoporosis
(Imported/Imported)

... after five years of treatment with Prempro, an estrogen and progesterone-based medication. Raloxifene (Evista) is a selective estrogen receptor modulator that is FDA-approved for the prevention and treatment ...

3. Simplified model predicts estrogen receptor-positive breast cancer risk
(Communities/Breast Mammary Gland)

... to either, the woman may be a candidate for a preventive intervention discussion regarding raloxifene or tamoxifen." "(The authors) have presented useful and important results that illustrate the promise ...

4. Anti-estrogen drug therapy reduces risk of invasive breast cancer in older women
(Communities/Breast Mammary Gland)

... took the drug raloxifene were less likely to develop invasive, estrogen-receptor (ER) positive breast cancer compared with women who did not take the drug. The results of the randomized controlled trial ...

5. Tibolone reduces risk of fractures and breast cancer but increases risk of stroke in older women
(Communities/Breast Mammary Gland)

... by 26 per cent. In addition tibolone reduced the risk of breast cancer. The effect of tibolone was comparable to those seen in women given the drugs tamoxifen or raloxifene. "The reduction in breast ...

6. Bazedoxifene reduces non-vertebral fracture risk in postmenopausal women
(Imported/Imported)

... raloxifene 60 mg or placebo daily. All subjects also received calcium 1,000-2,000 mg daily and vitamin D 400-800 IU daily. The overall incidence of non-vertebral fractures was similar among groups. However, ...

7. Raloxifene more cost-effective than alendronate
(Imported/Imported)

A cost-effectiveness analysis of raloxifene, alendronate and conservative care in post-menopausal women with osteopenia shows that raloxifene is less costly and more effective than alendronate in reducing ...

8. Many osteoporosis medications prevent fractures, but none is best
(Imported/Imported)

... fractures than estrogen, calcitonin or raloxifene, according to the report. Some agents, however, such as estrogen and raloxifene (a SERM), can have serious side effects such as strokes, blood clots in ...

9. Chronic kidney disease should not prevent women from taking the osteoporosis drug raloxifene
(Imported/Imported)

The osteoporosis drug raloxifene increases bone mineral density and reduces the risk of vertebral fractures among postmenopausal women with mild to moderate chronic kidney disease, according to a new ...

10. Anti-estrogen drug therapy reduces risk of invasive breast cancer in older women
(Communities/Breast Mammary Gland)

Tags: [estrogen-receptor(ER),Raloxifene,selective estrogen receptor modulator (SERM),ER-positive,coronary heart disease]  ...

11. Raloxifene more cost-effective than alendronate
(Imported/Imported)

Tags: [Raloxifene,more,cost-effective,than,alendronate]  ...

12. Chronic kidney disease should not prevent women from taking the osteoporosis drug raloxifene
(Imported/Imported)

Tags: [ Chronic,kidney,disease,should,not,prevent,women,from,taking,the,osteoporosis,drug,raloxifene ]  ...